Entera Bio (ENTX) AI Stock Analysis

• Market Cap: $91.33M
• Dividend Yield: N/A
• Average Volume (3M): 211.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 191.23%
• EPS Growth: 2.17%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 45,663,380
• 10 Day Avg. Volume: 96,006
• 30 Day Avg. Volume: 211,357
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 423.61
• Enterprise Value/Gross Profit: -10.05K
• Enterprise Value/Ebitda: -6.66
• 1Y Price Target: $10.00
• Price Target Upside: 400.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ―

Entera Bio's overall stock score reflects a balance between financial challenges and strategic advancements. The company's financial instability and cash flow issues weigh significantly on the score. However, positive corporate events and strong technical momentum provide some optimism, though valuation remains a concern due to negative earnings.

Positive Factors

Funding and Investment

OPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.

Partnership and Collaboration

Entera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.

Regulatory Approval

The FDA agreed to Entera Bio's proposal that the New Drug Application for its lead candidate EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study in women with post-menopausal osteoporosis.

Negative Factors

Regulatory Risk

The FDA’s potential landmark ruling on the SABRE ASBMR-FNIH regulatory endpoint for osteoporosis drugs is expected, which would be an additional risk-mitigating catalyst for the EB613 program.

Entera Bio Business Overview & Revenue Model

Company Description

Entera Bio Ltd. is a biotechnology company engaged in the development of orally delivered large molecule therapeutics. The company primarily operates within the pharmaceutical and biotechnology sectors, focusing on the advancement of oral formulations of injectable drugs. Entera Bio's core products aim to address unmet medical needs in areas like osteoporosis and hypoparathyroidism by providing more convenient oral delivery options for patients.

How the Company Makes Money

Entera Bio generates revenue through the development and commercialization of its proprietary oral drug formulations. The company's key revenue streams include collaborations and licensing agreements with other pharmaceutical companies. These partners may provide upfront payments, milestone payments, and royalties based on the sales of successfully developed drugs. Entera Bio's business model relies heavily on research and development activities, strategic partnerships, and the potential commercialization of its pipeline products.

Entera Bio Financial Statement Overview

Summary

Entera Bio faces significant financial challenges, with persistent losses, negative cash flows, and dependency on external financing. The income statement shows erratic revenue growth and weak profit margins, while the balance sheet reflects moderate leverage but negative shareholder returns. Cash flow management issues further emphasize financial instability.

Income Statement

Entera Bio has struggled with profitability, evidenced by consistently negative net income and EBIT over the years. The gross profit margin is weak, and the net profit margin is negative due to significant operating losses. The revenue growth is erratic, with revenue fluctuating significantly, highlighting instability in revenue generation.

Balance Sheet

The company's financial stability is moderate with a low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses, which impacts shareholder value. The equity ratio suggests a reasonable proportion of assets financed by equity, but overall balance sheet performance is hampered by ongoing losses.

Cash Flow

Cash flow management presents challenges, with negative operating cash flow and free cash flow across periods, indicating cash burn issues. The free cash flow to net income ratio is also negative, reflecting inefficiencies in converting income into cash. Financing activities have been crucial for liquidity, highlighting dependency on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	166.00K	181.00K	0.00	134.00K	571.00K	365.00K
Gross Profit	-7.00K	9.00K	-56.00K	33.00K	198.00K	156.00K
EBITDA	-10.56M	-9.54M	-8.80M	-12.87M	-12.16M	-11.11M
Net Income	-5.47M	-9.54M	-8.89M	-13.07M	-12.19M	-9.98M
Balance Sheet
Total Assets	19.67M	9.39M	11.77M	13.13M	25.99M	10.26M
Cash, Cash Equivalents and Short-Term Investments	10.86M	8.66M	11.02M	12.31M	24.89M	8.59M
Total Debt	203.00K	272.00K	390.00K	91.00K	302.00K	432.00K
Total Liabilities	2.41M	1.31M	1.38M	1.37M	3.42M	3.60M
Stockholders Equity	17.26M	8.08M	10.39M	11.75M	22.57M	6.67M
Cash Flow
Free Cash Flow	-6.70M	-6.82M	-7.33M	-12.55M	-9.08M	-10.48M
Operating Cash Flow	-6.66M	-6.82M	-7.31M	-12.50M	-9.06M	-10.42M
Investing Cash Flow	-40.00K	-3.00K	-17.00K	-102.00K	-17.00K	-86.00K
Financing Cash Flow	16.52M	4.48M	6.04M	13.00K	25.38M	3.92M

Entera Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Positive. The current price of 2 is above the 20-day moving average (MA) of 1.95, above the 50-day MA of 1.95, and below the 200-day MA of 2.01, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.00 is Neutral, neither overbought nor oversold. The STOCH value of 62.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTX.

Entera Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ENTX	50 Neutral	$91.33M	―	-82.22%	―	191.23%	2.17%
Sector *	47 Neutral	C$212.32M	-0.23	-30.33%	3.16%	19.38%	-2.35%
VTYX	41 Neutral	$201.80M	―	-48.56%	―	―	39.76%
JBIO	39 Underperform	$240.13M	―	-38.06%	32.00%	―	72.33%
TNYA	36 Underperform	$189.05M	―	-85.21%	―	―	38.94%
BDTX	33 Underperform	$157.14M	11.66	11.85%	―	―	―
ELTX	30 Underperform	$160.77M	―	-9999.00%	―	―	-4.60%

Entera Bio Corporate Events

Entera Bio Announces 2024 Financial Results and Updates

Entera Bio Ltd. announced its financial results and business updates for 2024, highlighting significant advancements in its oral peptide programs, including EB613 for osteoporosis, which is poised for a Phase 3 study pending FDA updates. The company also reported progress in its GLP-1/Glucagon and GLP-2 tablet programs, collaborating with OPKO Health to enhance its pipeline. Entera’s financial position was strengthened by investments, allowing it to fund operations into 2026, with a focus on regulatory and development activities.

Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon

On March 16, 2025, Entera Bio Ltd. entered into a collaboration and license agreement with OPKO Health, Inc. and OPKO Biologics Ltd. to develop an oral dual agonist GLP-1/glucagon peptide for treating obesity, metabolic, and fibrotic disorders. Under the agreement, Entera and OPKO will share development costs and proceeds, with Entera holding a 40% stake and OPKO 60%. Entera issued shares to OPKO to fund its share of development costs, and the collaboration aims to advance the first oral GLP-1/glucagon dual agonist into clinical trials, potentially impacting the treatment landscape for related disorders.